Testing tezepelumab for kids with severe asthma
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This study tests if tezepelumab can help reduce severe asthma attacks in children ages 5 to 11. It compares the drug to a placebo (a dummy treatment) to see if it is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is between 5 and 11 years old.
- Your child has been diagnosed with severe asthma for at least 6 months.
- Your child has been on daily asthma controller medicine for at least 3 months, with the same dose for the past month.
- Your child has had at least 2 severe asthma attacks in the last year, or 1 attack that required a hospital stay.
- Your child weighs at least 16 kg (about 35 pounds).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called tezepelumab to see if it helps control severe asthma in adults. It may be an option if your asthma is hard to manage with current treatments and you have frequent symptoms or flare-ups.
This trial tests a new medicine, QL2302, to see how well it works compared to an approved treatment called Tezspire for people with severe asthma. If you have asthma that is not well controlled despite using daily inhalers and other medications, you may be able to join.
This trial tests a new biologic drug (tezepelumab) to see if it improves symptoms in people with both chronic sinusitis with nasal polyps and severe asthma. The goal is to reduce inflammation and help you breathe better. Participants must not have had prior sinus surgery.
This trial tests a new drug called tozorakimab for adults whose asthma is not well controlled despite using medium-to-high dose inhaled steroids. The study aims to find the best dose and see if it reduces asthma attacks.
This trial tests if a new medicine, depemokimab, can help children aged 6 to 11 whose asthma is not well controlled with their current inhalers and who have a type of inflammation called eosinophilic asthma. It may reduce asthma attacks and improve symptoms.
This study tests if the medicine Dupilumab can help control asthma and wheezing in children ages 2 to just under 6. It is for children whose symptoms are not well-managed with their current inhaler.
Hear when a new Asthma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.